HomeCompareABBV vs BSX

ABBV vs BSX: Dividend Comparison 2026

ABBV yields 3.12% · BSX yields 3.18%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ABBV wins by $84.5K in total portfolio value
10 years
ABBV
AbbVie Inc.
● Live price
3.12%
Share price
$213.22
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$104.7K
Annual income
$25,725.73
Full ABBV calculator →
BSX
BSX
● Live price
3.18%
Share price
$62.93
Annual div
$2.00
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.2K
Annual income
$0.32
Full BSX calculator →

Portfolio growth — ABBV vs BSX

📍 ABBV pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodABBVBSX
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ABBV + BSX cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ABBV pays
BSX pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ABBV
Annual income on $10K today (after 15% tax)
$265.10/yr
After 10yr DRIP, annual income (after tax)
$21,866.87/yr
BSX
Annual income on $10K today (after 15% tax)
$270.14/yr
After 10yr DRIP, annual income (after tax)
$0.27/yr
At 15% tax rate, ABBV beats the other by $21,866.60/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ABBV + BSX for your $10,000?

ABBV: 50%BSX: 50%
100% BSX50/50100% ABBV
Portfolio after 10yr
$62.5K
Annual income
$12,863.02/yr
Blended yield
20.59%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on BSX right now

ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+20.1% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
BSX
Analyst Ratings
2
Strong
38
Buy
3
Hold
Consensus: Buy
Price Target
$108.35
+72.2% upside vs current
Range: $94.00 — $130.00
Altman Z
3.9
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ABBV buys
7
BSX buys
6
PoliticianChamberTickerTypeAmountDate
Gilbert Cisneros🏢 House$BSX▲ Buy$1,001 - $15,0002026-02-10
Gilbert Cisneros🏢 House$BSX▲ Buy$1,001 - $15,0002026-01-30
Markwayne Mullin🏛 Senate$BSX▲ Buy$15,001 - $50,0002025-12-29
Markwayne Mullin🏛 Senate$BSX▲ Buy$15,001 - $50,0002025-12-29
Gilbert Cisneros🏢 House$BSX▼ Sell$1,001 - $15,0002025-12-24
Julie Johnson🏢 House$ABBV▼ Sell$1,001 - $15,0002025-12-18
John Boozman🏛 Senate$BSX▼ Sell$1,001 - $15,0002025-12-17
John Boozman🏛 Senate$BSX▼ Sell$1,001 - $15,0002025-12-17
Julia Letlow🏢 House$ABBV▼ Sell$1,001 - $15,0002025-12-08
Gilbert Cisneros🏢 House$BSX▲ Buy$1,001 - $15,0002025-11-18
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricABBVBSX
Forward yield3.12%3.18%
Annual dividend / share$6.65$2.00
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR40.6%-50%
Portfolio after 10y$104.7K$20.2K
Annual income after 10y$25,725.73$0.32
Total dividends collected$63.0K$321.00
Payment frequencyquarterlyquarterly
SectorHealthcareHealthcare
Analyst consensusBuyBuy
Analyst price target$256.15$108.35

Year-by-year: ABBV vs BSX ($10,000, DRIP)

YearABBV PortfolioABBV Income/yrBSX PortfolioBSX Income/yrGap
1← crossover$11,559$438.51$10,859$158.91+$700.00ABBV
2$13,494$640.86$11,700$80.63+$1.8KABBV
3$15,951$945.97$12,559$40.60+$3.4KABBV
4$19,152$1,413.89$13,459$20.36+$5.7KABBV
5$23,443$2,146.38$14,411$10.20+$9.0KABBV
6$29,391$3,321.96$15,425$5.10+$14.0KABBV
7$37,948$5,265.87$16,507$2.55+$21.4KABBV
8$50,795$8,596.74$17,664$1.28+$33.1KABBV
9$71,034$14,549.41$18,901$0.64+$52.1KABBV
10$104,715$25,725.73$20,225$0.32+$84.5KABBV

ABBV vs BSX: Complete Analysis 2026

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →

BSXHealthcare

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, and atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, cryotherapy ablation systems, and micro and drainage catheters to treat cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.

Full BSX Calculator →
📬

Get this ABBV vs BSX comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ABBV vs JNJABBV vs MRKABBV vs PFEABBV vs BMYABBV vs LLYABBV vs SCHDABBV vs JEPIABBV vs O

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.